BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, Natalie Maimon Rabinovich et al.|Journal of Thoracic Oncology|2018Cited by 220
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Nir Peled, Mor Moskovitz et al.|Lung Cancer|2017Cited by 104
ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous ThromboembolismAlona Zer, Frances A. Shepherd, Mor Moskovitz et al.|Clinical Lung Cancer|2016Cited by 100
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg et al.|OncoImmunology|2021Cited by 70
The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective studyShlomit Strulov Shachar, Grant R. Williams, Gil Bar‐Sela et al.|Journal of Geriatric Oncology|2022Cited by 11